washington  reuters    u s  president donald trump on tuesday called on the pharmaceutical industry to boost u s  production and lower prices  while also vowing to speed up approval times for new medicines and appoint a new u s  food and drug administration leader soon   shares of five of the six drug companies at the white house meeting with trump were up more than  percent on average following the president s remarks  compared with a   percent drop in the broad s p   the nasdaq biotech index was up   percent  reversing earlier losses  and the s p  health care index gained   percent       attending the meeting were the ceos of novartis ag  merck   co inc  johnson   johnson  celgene corp  eli lilly   co and amgen inc as well as the head of the pharmaceutical research and manufacturers of america lobbying group  trump told the drugmakers that pricing had been  astronomical    we have to get prices down for a lot of reasons  we have no choice  for medicare and medicaid   trump said at the meeting  citing the nation s government insurance programs for the elderly  the poor and the disabled that together are the largest u s  purchaser of medications     trump also said currency devaluation by other countries had increased drugmakers  outsourcing their production and called on the companies to make more of their products in the united states   he added that foreign countries must pay fair share for drug development costs    we re going to end global freeloading   trump said   novartis  ceo joe jimenez  who is chairman elect of the industry lobbying group  said last week that he wanted to talk to trump about efforts to develop pricing models that would pay for clinical results rather than a flat price per pill  as well as plans to replace the affordable care act  which is popularly known as  obamacare   trump spooked investors in the pharmaceuticals and biotech sectors by saying on jan    before his inauguration  that drug companies were  getting away with murder  on what they charged the government for medicine and that he would do something about it   that prompted the pharmaceutical lobbying group to unveil a new tv marketing campaign last week to improve its image by focusing attention on strides in research  company executives  meanwhile  have tried to tread a careful line in defending their industry while expressing optimism that the united states would continue to reward scientific advances   